Sorbent Seeks A New Path To CV Therapy With Polymeric Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is trying to raise $30 million to fund a Phase IIb program for lead candidate in ESRD, plus bring a second compound into the clinic.